Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioMarin CEO Suggests Hemophilia Gene Therapy Pricing In $2m-$3m Range

Executive Summary

During BioMarin’s earnings call Feb. 21, CEO Bienaime indicated the company may be looking to price its valoctocogene roxaparvovec gene therapy at $2m-$3m, as it would represent a savings over the annual cost of infused clotting factor therapy.

Advertisement

Related Content

Novo Nordisk CSO: Hemophilia Treatment ‘Segmenting’ Much Like In Diabetes
Annuity Payment Model For Cures May Get Test Drive In Massachusetts
BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says
Hemophilia Seen As Good Testing Ground For Commercializing Gene Therapy
Spark's Gene Therapy Hemophilia Data Give Investors The Jitters
BioMarin Gets Second PKU Approval, Anticipates Slow Ramp-Up For Palynziq
BioMarin, Spark Hemophilia Gene Therapies Progress As Accelerated Approval Favors Their Indications
The First US Gene Therapy Maker Innovates On Pricing And Reimbursement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124718

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel